Bavarian Nordic A/S (announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) for Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older.

The submission represents a key milestone in the partnership established between Bavarian Nordic and Eurofarma and marks an important step toward making the vaccine available in one of the countries most affected by chikungunya. Brazil accounts for a substantial proportion of reported chikungunya cases and related deaths globally, underscoring the continued need for effective preventive measures against the disease.

Paul Chaplin, President & CEO of Bavarian Nordic, said: “The submission to Anvisa represents an important milestone in our strategy to expand access to our chikungunya vaccine beyond traditional travel markets and into regions where the disease poses a significant and recurring public health burden. Through our partnership with Eurofarma, we are combining global vaccine innovation with strong local expertise to support access for populations living at risk of chikungunya. We look forward to working closely with Eurofarma and Anvisa throughout the review process.”

João Siffert, Vice President of Innovation at Eurofarma, said: “The introduction of the vaccine reinforces Eurofarma’s commitment to expanding public access to innovative healthcare products capable of addressing important public health challenges with efficacy and safety. Chikungunya continues to spread in Brazil and generates a significant impact on patients, not only during the acute infection but also through chronic effects, affecting both patients and healthcare systems. This vaccine uses a modern and widely validated technology, with a favorable safety profile and the ability to induce a rapid immune response, contributing to strengthening disease prevention efforts.”